Key Laboratory of Microecology-Immune Regulatory Network and Related Diseases School of Basic Medicine, Jiamusi University, Jiamusi, Heilongjiang Province, China.
Tianjin First Central Hospital, Tianjin, China.
J Appl Biomater Funct Mater. 2024 Jan-Dec;22:22808000241289022. doi: 10.1177/22808000241289022.
Chronic bowel disease has the characteristics of high recurrence rate, prolonged and non-healing, and the incidence has increased year by year in recent years. Cannabidiol (CBD) has significant anti-inflammatory and antioxidant activities, but it is limited by its characteristics of fat solubility and low bioavailability. This study aims to treat chronic inflammatory bowel disease by preparing a CBD-loaded hydrogel system (GelMA + CBD) that can deliver CBD in situ and improve its bioavailability through slow release.
The study designed and constructed GelMA + CBD, and its surface morphology was observed by scanning electron microscopy, and its pore size, swelling rate and release rate were evaluated to evaluate its bioactivity and biosafety. The expression of various inflammatory factors was detected by ELISA, and the expression of protein and reactive oxygen species were observed by laser confocal microscopy to evaluate their anti-inflammatory and antioxidant properties.
Our study found that GelMA + CBD with biosafety, could make CBD be slowly released, and effectively inhibit the M1-type polarization of macrophages in vitro, and promote the M2-type polarization. In addition, GelMA + CBD can also reduce the expression of pro-inflammatory factors (such as iNOS) in macrophages, and increase the expression of anti-inflammatory factors (such as Arg-1), clear intracellular reactive oxygen species (ROS), and relieve oxidative stress.
The vitro experiments have confirmed that the CBD-loaded hydrogel system has good biosafety, and can alleviate inflammation by regulating the polarization direction of macrophages, and then inhibiting the secretion of pro-inflammatory factors, laying a strong foundation for the treatment of chronic enteritis.
慢性肠道疾病具有高复发率、病程长且难治愈的特点，近年来其发病率呈逐年上升趋势。大麻二酚（CBD）具有显著的抗炎和抗氧化活性，但由于其脂溶性和生物利用度低的特点而受到限制。本研究旨在通过制备一种可原位递送 CBD 并通过缓慢释放提高其生物利用度的 CBD 负载水凝胶系统（GelMA+CBD）来治疗慢性炎症性肠病。
本研究设计并构建了 GelMA+CBD，并通过扫描电子显微镜观察其表面形态，评估其孔径、溶胀率和释放率，以评估其生物活性和生物安全性。通过 ELISA 检测各种炎症因子的表达，通过激光共聚焦显微镜观察蛋白质和活性氧的表达，评估其抗炎和抗氧化特性。
我们的研究发现，具有生物安全性的 GelMA+CBD 能够使 CBD 缓慢释放，并有效抑制体外巨噬细胞 M1 型极化，促进 M2 型极化。此外，GelMA+CBD 还可以降低巨噬细胞中促炎因子（如 iNOS）的表达，增加抗炎因子（如 Arg-1）的表达，清除细胞内活性氧（ROS），减轻氧化应激。
体外实验证实，负载 CBD 的水凝胶系统具有良好的生物安全性，通过调节巨噬细胞的极化方向，减轻炎症反应，抑制促炎因子的分泌，为治疗慢性肠炎奠定了坚实的基础。
